3.5903 USD
+0.06 (+1.71%)
We assign a fundamental rating of 3 out of 10 to ABCL. ABCL was compared to 57 industry peers in the Life Sciences Tools & Services industry. While ABCL has a great health rating, there are worries on its profitability. ABCL is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ABCL has reported negative net income.
In the past year ABCL has reported a negative cash flow from operations.
In multiple years ABCL reported negative net income over the last 5 years.
In multiple years ABCL reported negative operating cash flow during the last 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -12.66%, ABCL is in line with its industry, outperforming 43.86% of the companies in the same industry.
ABCL has a Return On Equity (-17.81%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.66% | ||
| ROE | -17.81% | ||
| ROIC | N/A |
ROA(3y)-3.84%
ROA(5y)2.39%
ROE(3y)-5.09%
ROE(5y)2.8%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ABCL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ABCL does not have a ROIC to compare to the WACC, probably because it is not profitable.
ABCL has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ABCL has more shares outstanding
ABCL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
ABCL has an Altman-Z score of 1.54. This is a bad value and indicates that ABCL is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 1.54, ABCL perfoms like the industry average, outperforming 42.11% of the companies in the same industry.
There is no outstanding debt for ABCL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.54 |
ROIC/WACCN/A
WACC9.38%
2.3 Liquidity
A Current Ratio of 10.10 indicates that ABCL has no problem at all paying its short term obligations.
The Current ratio of ABCL (10.10) is better than 91.23% of its industry peers.
ABCL has a Quick Ratio of 10.10. This indicates that ABCL is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 10.10, ABCL belongs to the best of the industry, outperforming 91.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.1 | ||
| Quick Ratio | 10.1 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 6.56% over the past year.
Looking at the last year, ABCL shows a small growth in Revenue. The Revenue has grown by 7.16% in the last year.
The Revenue has been growing by 19.97% on average over the past years. This is quite good.
EPS 1Y (TTM)6.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.76%
Revenue 1Y (TTM)7.16%
Revenue growth 3Y-57.48%
Revenue growth 5Y19.97%
Sales Q2Q%37.62%
3.2 Future
The Earnings Per Share is expected to grow by 17.32% on average over the next years. This is quite good.
Based on estimates for the next years, ABCL will show a very strong growth in Revenue. The Revenue will grow by 44.85% on average per year.
EPS Next Y-22.09%
EPS Next 2Y-13.26%
EPS Next 3Y-5.21%
EPS Next 5Y17.32%
Revenue Next Year12.29%
Revenue Next 2Y11.18%
Revenue Next 3Y9.09%
Revenue Next 5Y44.85%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
ABCL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABCL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ABCL's earnings are expected to decrease with -5.21% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.26%
EPS Next 3Y-5.21%
5. Dividend
5.1 Amount
ABCL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:ABCL (12/19/2025, 3:24:59 PM)
3.5903
+0.06 (+1.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners37.54%
Inst Owner Change-4.17%
Ins Owners4.16%
Ins Owner Change0.08%
Market Cap1.07B
Revenue(TTM)35.32M
Net Income(TTM)-171.68M
Analysts81.43
Price Target10.03 (179.36%)
Short Float %22.04%
Short Ratio10.89
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.37%
Min EPS beat(2)-10.38%
Max EPS beat(2)29.13%
EPS beat(4)2
Avg EPS beat(4)11.26%
Min EPS beat(4)-10.38%
Max EPS beat(4)29.86%
EPS beat(8)4
Avg EPS beat(8)4.7%
EPS beat(12)6
Avg EPS beat(12)-140.57%
EPS beat(16)8
Avg EPS beat(16)-100.23%
Revenue beat(2)2
Avg Revenue beat(2)111.14%
Min Revenue beat(2)48.58%
Max Revenue beat(2)173.69%
Revenue beat(4)2
Avg Revenue beat(4)35.69%
Min Revenue beat(4)-44.84%
Max Revenue beat(4)173.69%
Revenue beat(8)3
Avg Revenue beat(8)10.63%
Revenue beat(12)3
Avg Revenue beat(12)-3.37%
Revenue beat(16)6
Avg Revenue beat(16)1.83%
PT rev (1m)5.9%
PT rev (3m)5.9%
EPS NQ rev (1m)-12.66%
EPS NQ rev (3m)-10.1%
EPS NY rev (1m)-7.92%
EPS NY rev (3m)-7.92%
Revenue NQ rev (1m)-9.64%
Revenue NQ rev (3m)-9.64%
Revenue NY rev (1m)7.23%
Revenue NY rev (3m)7.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 30.42 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.11 | ||
| P/tB | 1.23 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.57
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-0.51
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0.12
BVpS3.22
TBVpS2.93
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.66% | ||
| ROE | -17.81% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-3.84%
ROA(5y)2.39%
ROE(3y)-5.09%
ROE(5y)2.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 204.04% | ||
| Cap/Sales | 137.47% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 10.1 | ||
| Quick Ratio | 10.1 | ||
| Altman-Z | 1.54 |
F-Score5
WACC9.38%
ROIC/WACCN/A
Cap/Depr(3y)221.53%
Cap/Depr(5y)274.86%
Cap/Sales(3y)163.57%
Cap/Sales(5y)102.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.76%
EPS Next Y-22.09%
EPS Next 2Y-13.26%
EPS Next 3Y-5.21%
EPS Next 5Y17.32%
Revenue 1Y (TTM)7.16%
Revenue growth 3Y-57.48%
Revenue growth 5Y19.97%
Sales Q2Q%37.62%
Revenue Next Year12.29%
Revenue Next 2Y11.18%
Revenue Next 3Y9.09%
Revenue Next 5Y44.85%
EBIT growth 1Y15.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.14%
EBIT Next 3Y6.86%
EBIT Next 5Y5.3%
FCF growth 1Y-122.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1660.48%
OCF growth 3YN/A
OCF growth 5YN/A
ABCELLERA BIOLOGICS INC / ABCL FAQ
What is the ChartMill fundamental rating of ABCELLERA BIOLOGICS INC (ABCL) stock?
ChartMill assigns a fundamental rating of 3 / 10 to ABCL.
What is the valuation status of ABCELLERA BIOLOGICS INC (ABCL) stock?
ChartMill assigns a valuation rating of 0 / 10 to ABCELLERA BIOLOGICS INC (ABCL). This can be considered as Overvalued.
Can you provide the profitability details for ABCELLERA BIOLOGICS INC?
ABCELLERA BIOLOGICS INC (ABCL) has a profitability rating of 1 / 10.
Can you provide the financial health for ABCL stock?
The financial health rating of ABCELLERA BIOLOGICS INC (ABCL) is 7 / 10.